Welcome to Multibagg AI
Log in to access personalized features
IRIS
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Discovery themes featuring this stockBearish
4
Neutral
7
Bullish
3
Bearish
16
Neutral
11
Bullish
19
Bearish
12
Neutral
4
Bullish
16
Bearish
12
Neutral
4
Bullish
16
Bearish
12
Neutral
4
Bullish
16
Bearish
12
Neutral
4
Bullish
16
Upcoming Result Date: Nov 11, 2026
Shanmuga Hospital Limited is a multi‑specialty hospital headquartered in Salem, Tamil Nadu, providing tertiary clinical services including oncology, cardiology, robotic surgery and advanced diagnostics across a 150+ bed setup; the company converted to a public listed entity in 2024 and completed an IPO in February 2025.
H1 FY26 performance shows revenue of ₹24.62 crore, EBITDA of approx ₹4.61 crore and PAT of approx ₹2.70 crore, reflecting operating leverage from specialty services and accreditation-led trust; the hospital’s balance sheet and cash flows show ongoing investment in technology and capacity expansion.
The hospital differentiates via advanced oncology and surgical infrastructure — including LINAC radiotherapy machines, two modular OTs and a Da Vinci Xi robotic system — positioning Shanmuga Hospital Limited as a regional leader in complex procedures that can command higher tariffs and inbound patient flows.
Strategic initiatives include a planned increase of 50 inpatient beds, commissioning renal transplant services and a dedicated Nephro Care Centre, plus digital health integration via the planned 'Shanmuga Health App', indicating a push to scale volumes, diversify high-acuity services and improve patient experience and retention.
Promoter experience and institutional empanelments are strengths: promoters with 40+ years of healthcare experience, NABH and NABL accreditations, and tie-ups with government schemes and insurers support patient acquisition and cashless coverage for Shanmuga Hospital Limited, while promoter stake remains high at 72.1%.
Healthcare Services
Hospital
59 Cr
Moderate Risk
13.9
60.9
12.5
1.4
56.76
34.00
Sales CAGR
Profit CAGR
ROE
ROCE
Shanmuga Hospital Ltd (SHANMUGA) is currently trading at 43.00 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Shanmuga Hospital Limited is a multi‑specialty hospital headquartered in Salem, Tamil Nadu, providing tertiary clinical services including oncology, cardiology, robotic surgery and advanced diagnostics across a 150+ bed setup; the company converted to a public listed entity in 2024 and completed an IPO in February 2025. H1 FY26 performance shows revenue of ₹24.62 crore, EBITDA of approx ₹4.61 crore and PAT of approx ₹2.70 crore, reflecting operating leverage from specialty services and accreditation-led trust; the hospital’s balance sheet and cash flows show ongoing investment in technology and capacity expansion. The hospital differentiates via advanced oncology and surgical infrastructure — including LINAC radiotherapy machines, two modular OTs and a Da Vinci Xi robotic system — positioning Shanmuga Hospital Limited as a regional leader in complex procedures that can command higher tariffs and inbound patient flows. Strategic initiatives include a planned increase of 50 inpatient beds, commissioning renal transplant services and a dedicated Nephro Care Centre, plus digital health integration via the planned 'Shanmuga Health App', indicating a push to scale volumes, diversify high-acuity services and improve patient experience and retention. Promoter experience and institutional empanelments are strengths: promoters with 40+ years of healthcare experience, NABH and NABL accreditations, and tie-ups with government schemes and insurers support patient acquisition and cashless coverage for Shanmuga Hospital Limited, while promoter stake remains high at 72.1%.
Over the past 52 weeks, Shanmuga Hospital Ltd has traded between a low of ₹34.00 and a high of ₹56.76. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Shanmuga Hospital Ltd has a market capitalization of approximately 58.54. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Shanmuga Hospital Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 13.90 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 58.54 Cr, Shanmuga Hospital Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Shanmuga Hospital Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Shanmuga Hospital Ltd is 13.90. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
59.75 | 82 Cr | 27.53 | 2.01 | 0.00 | 7.29 | 18.00 | 4.87 | ||
39.60 | 74 Cr | 185.55 | 2.16 | 0.00 | 12.05 | 13.76 | 0.35 | ||
42.05 | 57 Cr | 13.60 | 1.35 | 0.00 | 9.91 | 12.37 | 7.93 | ||
22.85 | 52 Cr | 90.60 | 1.02 | 0.00 | 1.11 | 3.46 | 0.72 | ||
40.25 | 46 Cr | 8.02 | 0.88 | 0.00 | 26.06 | 12.11 | 0.00 | ||
45.00 | 31 Cr | -383.00 | 2.39 | 0.00 | -0.59 | -2.79 | -0.54 | ||
69.35 | 30 Cr | -8.17 | 0.00 | 0.00 | 219.47 | -11.64 | -13.57 | ||
| Median: 7 Co. | — | 42.05 | 52 Cr | 13.60 | 1.35 | 0.00 | 9.91 | 12.11 | 0.35 |
